Role of some T-lymphocyte subsets in assessment of treatment response in tuberculous patients

El-Shafey, Basem I.; El-Bedewy, Mohmad M.; Ezzat, Sherif; Attia, Mohmad

doi:10.1016/j.ejcdt.2015.03.006

Cited by 3 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…published data have shown that suPAR levels increase in patients with bacterial infections [10], sepsis [11], lung cancer [12], exacerbated chronic obstructive pulmonary disease [24], and acute respiratory distress syndrome [25]. Our findings are similar to those of previously published studies [13,14]: suPAR levels tended to decrease after initiating appropriate TB treatment and were higher in patients with an unsuccessful treatment outcome. Studies on sICAM-1 and suPAR with regard to TB diagnosis and TB treatment monitoring are lacking.…”

Section: Tablesupporting

confidence: 90%

See 1 more Smart Citation

Is analysis of inflammatory biomarkers and lymphocyte subpopulations useful in prediction of tuberculosis treatment outcomes?

Musteikienė

Miliauskas

Zaveckienė

et al. 2021

Journal of Clinical Tuberculosis and Other Mycobacterial Diseas

View full text Add to dashboard Cite

Section: Tablesupporting

confidence: 90%

“…Compared with CRP, suPAR has not been widely studied in pulmonary TB. Several studies have shown that suPAR may be useful in the prognosis and differentiation of TB [10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Is analysis of inflammatory biomarkers and lymphocyte subpopulations useful in prediction of tuberculosis treatment outcomes?

Musteikienė

Miliauskas

Zaveckienė

et al. 2021

Journal of Clinical Tuberculosis and Other Mycobacterial Diseas

View full text Add to dashboard Cite

“…The occurrence and development of TB are closely related to immunodeficiency (4,5), imbalance of Th1/Th2 immune response (6), and hypoimmunity (7)(8)(9). Chemotherapy only with antituberculosis drugs needs 6-9 months or even longer to kill the vast majority of MTB in the lesion (10,11). However, there may still be a small amount of persisting MTB in vivo, especially in macrophages, which is difficult to remove and becomes a "time bomb" for TB recurrence (12).…”

Section: Introductionmentioning

confidence: 99%

Immunotherapeutic mechanisms of ag85a/b DNA vaccine and its recovery effect on M. tuberculosis-induced injury

Wang,

Wu,

Liang

et al. 2024

Preprint

View full text Add to dashboard Cite

Our previous research developed a novel tuberculosis (TB) DNA vaccine ag85a/b showed a significant therapeutic effect on the mouse tuberculosis model by intramuscular injection (IM) and electroporation (EP). However, the action mechanisms between these two vaccine immunization methods remain unclear. In a previous study, 96 M. tuberculosis (MTB) H37Rv-infected BALB/c mice were treated with PBS, 10μg, 50μg, 100μg, and 200μg ag85a/b DNA vaccine delivered by IM and EP three times at two-week intervals, respectively. In this study, peripheral blood mononuclear cells (PBMCs) from 3 mice in each group were isolated to extract total RNA. The gene expression profiles were analyzed using gene microarray technology to obtain differentially expressed (DE) genes. Finally, DE genes were validated by real-time reverse transcription-quantitive PCR (RT-qPCR) and the GEO database. After MTB infection, most of the up-regulated DE genes were related to the digestion and absorption of nutrients or neuroendocrine, for example, Iapp, Scg2, Chga, Amy2a5, etc, and most of the down-regulated DE genes were related to cellular structural and functional proteins, especially the structure and function proteins of alveolar epithelial cell, for example, Sftpc, Sftpd, Pdpn, etc. Most of the abnormally up-regulated or down-regulated DE genes in the TB model group were recovered in the 100μg and 200μg ag85a/b DNA IM groups and four DNA EP groups. The pancreatic secretion pathway down-regulated and Rap1 signal pathway up-regulated had particularly significant changes during the immunotherapy of the ag85a/b DNA vaccine on the mouse TB model. The action target and mechanism of IM and EP are highly consistent. Tuberculosis infection caused rapid catabolism and slow anabolism in mice. For the first time, we found that the effective dose of the ag85a/b DNA vaccine immunized whether by IM or EP could significantly up-regulate immune-related pathways and recover the metabolic disorder and the injury caused by MTB.

show abstract

“…The occurrence and development of TB are closely related to immunodeficiency, 4,5 imbalance of Th1/Th2 immune response, 6 and hypoimmunity 7–9 . Chemotherapy only with anti‐TB drugs needs 6–9 months or even longer to kill the vast majority of MTB in the lesion 10,11 . However, there may still be a small amount of persisting MTB in vivo, especially in macrophages, which is difficult to remove and becomes a “time bomb” for TB recurrence 12 .…”

Section: Introductionmentioning

confidence: 99%

“… 7 , 8 , 9 Chemotherapy only with anti‐TB drugs needs 6–9 months or even longer to kill the vast majority of MTB in the lesion. 10 , 11 However, there may still be a small amount of persisting MTB in vivo, especially in macrophages, which is difficult to remove and becomes a “time bomb” for TB recurrence. 12 Anti‐TB immunoadjuvant therapy with immunomodulators has great potential in preventing latent MTB reactivation and treating active TB patients.…”

Section: Introductionmentioning

confidence: 99%

Mechanisms of ag85a/b DNA vaccine conferred immunotherapy and recovery from Mycobacterium tuberculosis‐induced injury

Wang,

Liang,

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

Our previous research developed a novel tuberculosis (TB) DNA vaccine ag85a/b that showed a significant therapeutic effect on the mouse tuberculosis model by intramuscular injection (IM) and electroporation (EP). However, the action mechanisms between these two vaccine immunization methods remain unclear. In a previous study, 96 Mycobacterium tuberculosis (MTB) H37Rv‐infected BALB/c mice were treated with phosphate‐buffered saline, 10, 50, 100, and 200 μg ag85a/b DNA vaccine delivered by IM and EP three times at 2‐week intervals, respectively. In this study, peripheral blood mononuclear cells (PBMCs) from three mice in each group were isolated to extract total RNA. The gene expression profiles were analyzed using gene microarray technology to obtain differentially expressed (DE) genes. Finally, DE genes were validated by real‐time reverse transcription‐quantitive polymerase chain reaction and the GEO database. After MTB infection, most of the upregulated DE genes were related to the digestion and absorption of nutrients or neuroendocrine (such as Iapp, Scg2, Chga, Amy2a5), and most of the downregulated DE genes were related to cellular structural and functional proteins, especially the structure and function proteins of the alveolar epithelial cell (such as Sftpc, Sftpd, Pdpn). Most of the abnormally upregulated or downregulated DE genes in the TB model group were recovered in the 100 and 200 μg ag85a/b DNA IM groups and four DNA EP groups. The pancreatic secretion pathway downregulated and the Rap1 signal pathway upregulated had particularly significant changes during the immunotherapy of the ag85a/b DNA vaccine on the mouse TB model. The action targets and mechanisms of IM and EP are highly consistent. Tuberculosis infection causes rapid catabolism and slow anabolism in mice. For the first time, we found that the effective dose of the ag85a/b DNA vaccine immunized whether by IM or EP could significantly up‐regulate immune‐related pathways and recover the metabolic disorder and the injury caused by MTB.

show abstract

Role of some T-lymphocyte subsets in assessment of treatment response in tuberculous patients

Cited by 3 publications

References 29 publications

Is analysis of inflammatory biomarkers and lymphocyte subpopulations useful in prediction of tuberculosis treatment outcomes?

Is analysis of inflammatory biomarkers and lymphocyte subpopulations useful in prediction of tuberculosis treatment outcomes?

Immunotherapeutic mechanisms of ag85a/b DNA vaccine and its recovery effect on M. tuberculosis-induced injury

Mechanisms of ag85a/b DNA vaccine conferred immunotherapy and recovery from Mycobacterium tuberculosis‐induced injury

Contact Info

Product

Resources

About